Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Cipla
Daiichi Sankyo
US Department of Justice
Queensland Health
Fish and Richardson
Express Scripts
Chinese Patent Office
McKinsey
Deloitte

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,298,576

« Back to Dashboard

Which drugs does patent 8,298,576 protect, and when does it expire?

Patent 8,298,576 protects TROKENDI XR and is included in one NDA.

This patent has eleven patent family members in eight countries.
Summary for Patent: 8,298,576
Title:Sustained-release formulations of topiramate
Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
Inventor(s): Liang; Likan (Boyds, MD), Wang; Hua (Clarksville, MD), Bhatt; Padmanabh P. (Rockville, MD), Vieira; Michael L. (Gaithersburg, MD)
Assignee: Supernus Pharmaceuticals, Inc. (Rockville, MD)
Application Number:11/941,475
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Use;

Drugs Protected by US Patent 8,298,576

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-001 Aug 16, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-001 Aug 16, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y TREATMENT OF EPILEPSY ➤ Subscribe
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-002 Aug 16, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-002 Aug 16, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y TREATMENT OF EPILEPSY ➤ Subscribe
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-003 Aug 16, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-003 Aug 16, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y TREATMENT OF EPILEPSY ➤ Subscribe
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-004 Aug 16, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y TREATMENT OF EPILEPSY ➤ Subscribe
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-004 Aug 16, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,298,576

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,992,989 Sustained-release formulations of topiramate ➤ Subscribe
8,298,580 Sustained-release formulations of topiramate ➤ Subscribe
9,622,983 Sustained-release formulations of topiramate ➤ Subscribe
8,663,683 Sustained-release formulations of topiramate ➤ Subscribe
9,549,940 Sustained-release formulations of topiramate ➤ Subscribe
8,889,191 Sustained-release formulations of topiramate ➤ Subscribe
8,877,248 Sustained-release formulations of topiramate ➤ Subscribe
9,555,004 Sustained-release formulations of topiramate ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,298,576

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Mexico 2009001711 ➤ Subscribe
Japan 5489719 ➤ Subscribe
Japan 2010510241 ➤ Subscribe
Spain 2555066 ➤ Subscribe
Spain 2312308 ➤ Subscribe
European Patent Office 2394643 ➤ Subscribe
European Patent Office 1973528 ➤ Subscribe
Germany 07870164 ➤ Subscribe
Canada 2618240 ➤ Subscribe
Australia 2007319141 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Accenture
Citi
Merck
Covington
McKesson
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot